A study of postoperative cytostatic medication in patients with operable carcinoma of the lung.
D000230:Adenocarcinoma / Q000145:classification; D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000145:classification; D000328:Adult; D000368:Aged; D001859:Bone Neoplasms; D001932:Brain Neoplasms / Q000517:prevention & control; D002283:Carcinoma, Bronchogenic / Q000145:classification; D018288:Carcinoma, Small Cell / Q000145:classification; D002294:Carcinoma, Squamous Cell / Q000145:classification; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D005500:Follow-Up Studies; D006801:Humans; D008113:Liver Neoplasms / Q000517:prevention & control; D008175:Lung Neoplasms / Q000145:classification / Q000601:surgery*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D011183:Postoperative Complications / Q000517:prevention & control*; D011379:Prognosis; D013997:Time Factors
D003520:Cyclophosphamide